<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02772419</url>
  </required_header>
  <id_info>
    <org_study_id>4563-005</org_study_id>
    <nct_id>NCT02772419</nct_id>
  </id_info>
  <brief_title>Study of Benralizumab (KHK4563) in Patients With Eosinophilic Chronic Rhinosinusitis</brief_title>
  <official_title>A Phase 2, Double-Blind, Placebo-Controlled Study of Benralizumab (KHK4563) in Patients With Eosinophilic Chronic Rhinosinusitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Hakko Kirin Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Hakko Kirin Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy and safety of SC administrations of
      Benralizumab or Placebo in the subjects with Eosinophilic Chronic Rhinosinusitis in a
      multicenter, randomized, double-blind, placebo-controlled study. The pharmacokinetics and
      immunogenicity will be assessed secondarily.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Screening Period (maximum 4 weeks) , Randomized Treatment Period (24 weeks)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Actual">March 27, 2017</completion_date>
  <primary_completion_date type="Actual">March 27, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change from baseline in nasal polyp score at Week 12</measure>
    <time_frame>baseline and 12 weeks post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in nasal polyp score</measure>
    <time_frame>Pre-dose and 4,8,12,16,20,24 weeks post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in Computed tomography (CT) score</measure>
    <time_frame>baseline and 12 weeks post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects discontinued from the study due to aggravation of eosinophilic chronic rhinosinusitis</measure>
    <time_frame>Up to 24 weeks after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to discontinuation (days) from the study due to aggravation of eosinophilic chronic rhinosinusitis</measure>
    <time_frame>Up to 24 weeks after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in Blood eosinophil count</measure>
    <time_frame>Pre-dose and 4,8,12,16,20,24 weeks post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in Nasal Airway Resistance</measure>
    <time_frame>Pre-dose and 4,8,12,24 weeks post-dose</time_frame>
    <description>Nasal airway resistance (Pa/cm^3/s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in the averaged values of the Olfactory thresholds</measure>
    <time_frame>Pre-dose and 4,8,12,24 weeks post-dose</time_frame>
    <description>Olfactory thresholds are assessed by T&amp;T Olfactometer Test Score (Five kinds of smell with eight (5 to -2) phases).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in the improvement of olfactory dysfunction</measure>
    <time_frame>Pre-dose and 4,8,12,24 weeks post-dose</time_frame>
    <description>Olfactory dysfunction (1 to 5) is calculated by the Olfactory thresholds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in Sino-Nasal Outcome Test-2 (SNOT-22)</measure>
    <time_frame>Pre-dose and 4,8,12, 16, 20, 24 weeks post-dose</time_frame>
    <description>Symptom score are assessed by VAS (nasal congestion, anterior and posterior nasal drip, loss of the sense of smell, headache, and impairment in activity of daily living)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in Symptom score by Visual Analog Scale (VAS)</measure>
    <time_frame>Pre-dose and 4,8,12, 16, 20, 24 weeks post-dose</time_frame>
    <description>Symptom score are assessed by VAS (nasal congestion, anterior and posterior nasal drip, loss of the sense of smell, headache, and impairment in activity of daily living)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs) or drug-related TEAEs and their nature</measure>
    <time_frame>Up to 24 weeks after dosing</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum concentration of benralizumab</measure>
    <time_frame>Pre-dose and 4, 8, 12, 16, 20, 24 days post-dose</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Eosinophilic Chronic Rhinosinusitis</condition>
  <arm_group>
    <arm_group_label>benralizumab A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous (SC) administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>benralizumab B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SC administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo SC administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>benralizumab</intervention_name>
    <description>SC administration</description>
    <arm_group_label>benralizumab A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>benralizumab</intervention_name>
    <description>SC administration</description>
    <arm_group_label>benralizumab B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>SC administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 20 years to 75 years of age

          -  Eosinophilic chronic rhinosinusitis with a total score of ≥ 11 according to the
             diagnosis of eosinophilic chronic rhinosinusitis at enrollment

          -  A minimum bilateral nasal polyp score of 3 out of the maximum score of 8 (with a score
             of at least 1 out of the maximum score of 4 for each nostril) at screening and at
             enrollment

          -  Weight of ≥ 40 kg at screening

        Exclusion Criteria:

          -  A Sino-Nasal Outcome Test-22 (SNOT-22) score of &lt; 7 at enrollment

          -  Any nasal surgery (including polypectomy) within 1 year prior to the date of consent

          -  Hospitalization for ≥ 24 hours for treatment of asthma exacerbation, within 12 weeks
             prior to the date of consent

          -  Exposure to any commercially available (e.g., omalizumab) or investigational biologic
             agent within 16 weeks or 5 half-lives prior to enrollment, whichever is longer

          -  Use of systemic corticosteroids (including oral corticosteroids) or corticosteroid
             nasal solution (except spraying) within 4 weeks prior to enrollment or planned use of
             such medications during the double-blind period

          -  Prior treatment with benralizumab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Tokunaga T, Sakashita M, Haruna T, Asaka D, Takeno S, Ikeda H, Nakayama T, Seki N, Ito S, Murata J, Sakuma Y, Yoshida N, Terada T, Morikura I, Sakaida H, Kondo K, Teraguchi K, Okano M, Otori N, Yoshikawa M, Hirakawa K, Haruna S, Himi T, Ikeda K, Ishitoya J, Iino Y, Kawata R, Kawauchi H, Kobayashi M, Yamasoba T, Miwa T, Urashima M, Tamari M, Noguchi E, Ninomiya T, Imoto Y, Morikawa T, Tomita K, Takabayashi T, Fujieda S. Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC Study. Allergy. 2015 Aug;70(8):995-1003. doi: 10.1111/all.12644. Epub 2015 May 26.</citation>
    <PMID>25945591</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2016</study_first_submitted>
  <study_first_submitted_qc>May 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2016</study_first_posted>
  <last_update_submitted>April 20, 2018</last_update_submitted>
  <last_update_submitted_qc>April 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

